UR Home
![]() | Up a level |
and Daneshmand, Siamak
(2022)
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.
Future Oncology 18 (21), pp. 2599-2614.
Fulltext not available.
Publication Server
Publishing: oa@ur.de
0941 943 -4239 or -69394
Dissertations: dissertationen@ur.de
0941 943 -3904
Research data: datahub@ur.de
0941 943 -5707